Depemokimab’s Secondary Stumbles In Asthma

GSK’s ultra-long-acting biologic cuts asthma attacks, but misses on all the secondary endpoints in the twin SWIFT trials could limit its appeal.    

labcoat
• Source: GSK

What price convenience? That is the question raised by the full data from the twin pivotal studies of GSK plc’s asthma candidate, depemokimab. The anti-IL-5 antibody reduced asthma attacks by a similar degree to a handful of marketed asthma biologics, but it is injected just twice a year, whereas most of its rivals are monthly jabs.

Key Takeaways
  • GSK’s anti-IL-5 antibody depemokimab cut the annualized rate of asthma attacks by 58% and 48% versus placebo in the pivotal SWIFT-1 and SWIFT-2 trials, respectively.

Full data from the Phase III SWIFT-1 and SWIFT-2 trials in eosinophilic asthma were presented at the European Respiratory Society...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Takeda Prepares Ground For Oveporexton In Narcolepsy

 

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By 

Paying €90m upfront for rights to generalized pustular psoriasis drug.

Pipeline Watch: Ten Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Capricor Gets Complete Response For DMD Cell Therapy

 
• By 

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

More from R&D

Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat

 

Rivals Mineralys could be first to file but AstraZeneca is banking on its cardiovascular market know-how to lead the emerging class.

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By 

Paying €90m upfront for rights to generalized pustular psoriasis drug.

Pipeline Watch: Ten Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.